Table 4.

Selected published results of SRS (2000–2015) for the treatment of prolactin-secreting pituitary adenomas

Authors	Patients	Type	dose	Follow-up	Tumor	Biochemical	Late toxicity (%)
		of SRS	(Gy)	(months)	control (%)	remission (%)	visual	hypopituitarism
Landolt 2000 [124]	20	GK	29	25	85	25	0	NA
Pan L et al., 2000 [125]	128	GK	33	41	99	41	0	NA
Izawa et al., 2000 [85]	15	GK	23.6	16	100	16	0	NA
Feigl et al., 2002 [32]	18	GK	15a	55	94	60	NA	40
Choi et al., 2003 [126]	21	GK	28.5a	42.5	96.9	23.8	0	0
Petrovich et al., 2003 [60]	12	GK	15a	41	83	83	0	4
Pouratian et al., 2006 [127]	23	GK	18.6a	55	89	26	7	28
Voges et al., 2006 [66]	13	LINAC	20	56	100	15.4	4.2	18.3
Pollock et al., 2008 [118]	11	GK	18a	48	100	18 at 4 years	9.1	36
Castinetti et al., 2009 [100]	15	GK	28a	96	100	46.6	0	21
Jezkova et al., 2009 [128]	35	GK	34a	75.5	97	37.1	0	14.3
Wan et al., 2009 [98]	176	GK	22.4a	67.5	90.3	23.3	0	1.8
Tanaka et al., 2010 [129]	22	GK	25a	60	100	18	4	42 at 4 years
Sheehan et al., 2011 [36]	32	GK	24a	31	93	26	2.4	24.4
Liu et al., 2013 [130]	22	GK	15a	36	86	27.3	0	4.5
Wattson et al., 2014 [109]	9	Protons	20	60	98	22	0	57
Cohen-Inbar et al., 2015 [131]	38	GK	25a	42.3	92	50	4.2	30.3

SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed

^amarginal dose